TARGET-seq uniquely enabled phenotypic and molecular characterization of rare TP53-WT cells, referred to as pre-LSCs, which include both residual HSPCs that were WT for all mutations analyzed, as well as HSPCs that form part of the antecedent MPN clone. This evidence concerns the gene TP53 and myeloproliferative disorder.